Brief: Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million
13/03/2025 21:37
March 13 (Reuters) - Enliven Therapeutics Inc ELVN.O: ENLIVEN THERAPEUTICS Q4 OPERATING EXPENSES USD 26.896 MILLION ENLIVEN THERAPEUTICS Q4 NET INCOME USD -23.18 MILLION ENLIVEN THERAPEUTICS Q4 INCOME FROM OPERATIONS USD -26.896 MILLION ENLIVEN THERAPEUTICS Q4 BASIC EPS USD -0.46 Source text: ID:nPn3JnRfGa Further company coverage: ELVN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses